Myeloma Combo With 'Unprecedented' Effect Wins FDA Approval

Teclistamab- daratumumab combination earns FDA approval in relapsed, refractory myeloma

The FDA has approved teclistamab-cqyv in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who received at least one prior line of therapy.As the third approval under the Commissioner’s National Priority Voucher pilot program, teclistamab-cqyv (Tecvayli, Johnson & Johnson) plus daratumumab hyaluronidase-fihj (Darzalex Faspro, Johnson

Myeloma Combo With 'Unprecedented' Effect Wins FDA Approval

(MedPage Today) -- A promising combination for multiple myeloma received FDA approval as a second-line therapy. The approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase (Darzalex Faspro) stipulates use in patients who have received...

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line - PressReach

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression–free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit HORSHAM, Pa., March 5, 2026 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA)…

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

J&J has announced the US FDA approval for the combination of Tecvayli and Darzalex Faspro for adults with RRMM.

Tecvistamab Approved for Relapsed/Refractory Multiple Myeloma

Archyde In a significant advancement for patients battling multiple myeloma, the U.S. Food and Drug Administration (FDA) has granted approval to a combination therapy featuring teclistamab and daratumumab hyaluronidase-fihj. This approval,… You can read the full story here: Tecvistamab Approved for Relapsed/Refractory Multiple Myeloma.